Monitoring methotrexate hepatic toxicity in rheumatoid arthritis: Is it time to update the guidelines?

Journal of Rheumatology

Volumn 29, Issue 8, 2002, Pages 1586-1589

  Yazici, Yusuf ^a   Erkan, Doruk ^a   Paget, Stephen A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT;

ALGORITHM; BONE MARROW SUPPRESSION; COST EFFECTIVENESS ANALYSIS; EDITORIAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOALBUMINEMIA; LEUKOPENIA; LIVER BIOPSY; LIVER TOXICITY; LUNG DISEASE; MONOCYTOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN DISEASE; STOMATITIS; DRUG MONITORING; ECONOMICS; HOSPITAL; METHODOLOGY; NOTE; RHEUMATOLOGY; TOXIC HEPATITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG MONITORING; HEPATITIS, TOXIC; HOSPITALS, SPECIAL; HUMAN; METHOTREXATE; PRACTICE GUIDELINES; RHEUMATOLOGY; HUMANS;

EID: 0036021118     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. The changing face of rheumatoid arthritis therapy: Results of serial surveys
2. Temporary remission in acute leukemia in children produced by folic acid antagonist 4-amethopteroylglutamicacid (aminopterin)
3. Hepatotoxicity of long-term methotrexate therapy for psoriasis
4. Hepatotoxicity of methotrexate in the treatment of psoriasis
5. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity
6. Evidence-based medicine or medicines-based evidence?
7. Monitoring for methotrexate hepatic toxicity in RA patients: Is it time to update the guidelines?
8. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
9. Efficacy of low-dose methotrexate in rheumatoid arthritis
10. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
11. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double blind trial
12. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis
13. A long-term prospective study of the use of methotrexate in rheumatoid arthritis. Update after a mean of fifty-three months
14. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months
15. Methotrexate in rheumatoid arthritis: Effects on disease activity in a multicenter prospective study
16. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis
17. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-Month update
18. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis
19. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
20. Methotrexate in psoriasis: Revised guidelines
21. Early rheumatoid arthritis: Time to aim for remission?
22. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials
23. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years
24. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis
25. Suggested guidelines for monitoring liver toxicity in rheumatoid arthritis patients treated with methotrexate: Comment on article by Kremer et al [letter]
26. Creating a care-effective cost-effective strategy for methotrexate liver toxicity monitoring in rheumatoid arthritis: Comment on article by Kremer et al [letter]